{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T12:18:25Z","timestamp":1795177105360,"version":"4.10.3"},"reference-count":30,"publisher":"Elsevier BV","issue":"10020","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/s0140-6736(15)01159-9","type":"journal-article","created":{"date-parts":[[2015,12,15]],"date-time":"2015-12-15T16:28:36Z","timestamp":1450196916000},"page":"760-769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":939,"title":["Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial"],"prefix":"10.1016","volume":"387","clinical-trial-number":[{"clinical-trial-number":"nct00412893","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Johan A","family":"Maertens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issam I","family":"Raad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieren A","family":"Marr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios P","family":"Kontoyiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J","family":"Bow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galia","family":"Rahav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysios","family":"Neofytos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Aoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W","family":"Baddley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Giladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner J","family":"Heinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Herbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinolf","family":"Karthaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Gun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki A","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Oren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Selleslag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shmuel","family":"Shoham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle M","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Hortense","family":"Schmitt-Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhardt","family":"Zeiher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Ullmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(15)01159-9_bib1","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3201\/eid2007.140087","article-title":"Population-based analysis of invasive fungal infections, France, 2001-2010","volume":"20","author":"Bitar","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/S0140-6736(15)01159-9_bib2","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/j.1469-0691.2011.03548.x","article-title":"Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005\u20132007)","volume":"17","author":"Lortholary","year":"2011","journal-title":"Clin Microbiol Infect"},{"issue":"suppl 4","key":"10.1016\/S0140-6736(15)01159-9_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1469-0691.2008.01984.x","article-title":"Liposomal amphotericin B: what is its role in 2008?","volume":"14","author":"Lanternier","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/S0140-6736(15)01159-9_bib4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jinf.2014.01.007","article-title":"Micafungin for the treatment of invasive aspergillosis","volume":"68","author":"Enoch","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/S0140-6736(15)01159-9_bib5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bmt.2009.334","article-title":"Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study","volume":"45","author":"Herbrecht","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/S0140-6736(15)01159-9_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S0140-6736(15)01159-9_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S0140-6736(15)01159-9_bib8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bmt.2010.175","article-title":"European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3\u20142009 update","volume":"46","author":"Maertens","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 3","key":"10.1016\/S0140-6736(15)01159-9_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1469-0691.12465","article-title":"ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others","volume":"20","author":"Tortorano","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/S0140-6736(15)01159-9_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1179\/1973947812Y.0000000051","article-title":"Voriconazole in clinical practice","volume":"24","author":"Mikulska","year":"2012","journal-title":"J Chemother"},{"key":"10.1016\/S0140-6736(15)01159-9_bib11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.50.1.279-285.2006","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/S0140-6736(15)01159-9_bib12","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1128\/AAC.01355-13","article-title":"Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/S0140-6736(15)01159-9_bib13","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1128\/AAC.02301-13","article-title":"Isavuconazole therapy protects immunosuppressed mice from mucormycosis","volume":"58","author":"Luo","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/S0140-6736(15)01159-9_bib14","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1128\/AAC.01354-13","article-title":"Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/S0140-6736(15)01159-9_bib15","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1128\/AAC.04055-14","article-title":"Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method","volume":"59","author":"Espinel-Ingroff","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/S0140-6736(15)01159-9_bib16","author":"Astellas Pharma"},{"key":"10.1016\/S0140-6736(15)01159-9_bib18","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S0140-6736(15)01159-9_bib20","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/clinids\/23.3.608","article-title":"Therapeutic outcome in invasive aspergillosis","volume":"23","author":"Denning","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S0140-6736(15)01159-9_bib21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(15)01159-9_bib22","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1086\/653065","article-title":"Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"51","author":"Spellberg","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S0140-6736(15)01159-9_bib23","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1634\/theoncologist.2010-0290","article-title":"Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles","volume":"16","author":"Ramos","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/S0140-6736(15)01159-9_bib24","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S0140-6736(15)01159-9_bib25","first-page":"163","article-title":"Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections","volume":"6","author":"Falci","year":"2013","journal-title":"Infect Drug Resist"},{"key":"10.1016\/S0140-6736(15)01159-9_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0140-6736(15)01159-9_bib27","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/cncr.23441","article-title":"Changes in causes of death over time after treatment for invasive aspergillosis","volume":"112","author":"Wingard","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/S0140-6736(15)01159-9_bib28","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cncr.22738","article-title":"Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications","volume":"110","author":"Miceli","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/S0140-6736(15)01159-9_bib29","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S0140-6736(15)01159-9_bib30","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S0140-6736(15)01159-9_bib31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cis437","article-title":"Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections","volume":"55","author":"Pascual","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S0140-6736(15)01159-9_bib32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270005283837","article-title":"Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities","volume":"46","author":"Tan","year":"2006","journal-title":"J Clin Pharmacol"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673615011599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673615011599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T13:31:16Z","timestamp":1668605476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673615011599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":30,"journal-issue":{"issue":"10020","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0140673615011599"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(15)01159-9","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726024829.793512570","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.726024829.793532783","asserted-by":"object"}]},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(15)01159-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(15)01218-0","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}